The DOI matches its Crossref record; 717 of the 717 references it cites were found in a registry or an index.
ImmunoPET: Concept, Design, and Applications
Open accessAbstract
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) and the inherent sensitivity of PET technique. A variety of radionuclides and mAbs have been exploited to develop immunoPET probes, which has been driven by the development and optimization of radiochemistry and conjugation strategies. In addition, tumor-targeting vectors with a short circulation time (e.g., Nanobody) or with an enhanced binding affinity (e.g., bispecific antibody) are being used to design novel immunoPET probes. Accordingly, several immunoPET probes, such as 89 Zr-Df-pertuzumab and 89 Zr-atezolizumab, have been successfully translated for clinical use. By noninvasively and dynamically revealing the expression of heterogeneous tumor antigens, immunoPET imaging is gradually changing the theranostic landscape of several types of malignancies. ImmunoPET is the method of choice for imaging specific tumor markers, immune cells, immune checkpoints, and inflammatory processes. Furthermore, the integration of immunoPET imaging in antibody drug development is of substantial significance because it provides pivotal information regarding antibody targeting abilities and distribution profiles. Herein, we present the latest immunoPET imaging strategies and their preclinical and clinical applications. We also emphasize current conjugation strategies that can be leveraged to develop next-generation immunoPET probes. Lastly, we discuss practical considerations to tune the development and translation of immunoPET imaging strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 717
Heist, R. S., Guarino, M. J., Masters, G., Purcell, W. T., Starodub, A. N., Horn, L., Scheff, R. J., Bardia, A., Messersmith, W. A., Berlin, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1894 · Cited by 193
Donnelly, D. J., Smith, R. A., Morin, P., Lipovšek, D., Gokemeijer, J., Cohen, D., Lafont, V., Tran, T., Cole, E. L., Wright, M., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.199596 · Cited by 193
Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy
Ni, D., Ferreira, C. A., Barnhart, T. E., Quach, V., Yu, B., Jiang, D., Wei, W., Liu, H., Engle, J. W., Hu, P., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b09374 · Cited by 192
Self-citationUlaner, G. A., Hyman, D. M., Ross, D. S., Corben, A., Chandarlapaty, S., Goldfarb, S., McArthur, H., Erinjeri, J. P., Solomon, S. B., Kolb, H., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.172031 · Cited by 191
Cai, W., Wu, Y., Chen, K., Cao, Q., Tice, D. A., & Chen, X. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1480 · Cited by 187
Self-citationFcγ Receptor Function and the Design of Vaccination Strategies
Bournazos, S., & Ravetch, J. V. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.009 · Cited by 185
Kaittanis, C., Andreou, C., Hieronymus, H., Mao, N., Foss, C. A., Eiber, M., Weirich, G., Panchal, P., Gopalan, A., Zurita, J., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171052 · Cited by 185
Rossin, R., Läppchen, T., van den Bosch, S. M., Laforest, R., & Robillard, M. S. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.123745 · Cited by 183
Design of an Optimized Scaffold for Affibody Molecules
Feldwisch, J., Tolmachev, V., Lendel, C., Herne, N., Sjöberg, A., Larsson, B., Rosik, D., Lindqvist, E., Fant, G., Höidén-Guthenberg, I., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.002 · Cited by 181
Involvement of platelet‐derived growth factor ligands and receptors in tumorigenesis
Heldin, C. ‐., Lennartsson, J., & Westermark, B. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12690 · Cited by 181
Ulaner, G. A., Lyashchenko, S. K., Riedl, C., Ruan, S., Zanzonico, P. B., Lake, D., Jhaveri, K., Zeglis, B., Lewis, J. S., & O’Donoghue, J. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.202010 · Cited by 179
What did we learn from CTLA‐4 insufficiency on the human immune system?
Mitsuiki, N., Schwab, C., & Grimbacher, B. (2019) · Immunological Reviews · doi:10.1111/imr.12721 · Cited by 177
Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases
Hafeez, U., Gan, H. K., & Scott, A. M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.05.010 · Cited by 176
CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
Morandi, F., Horenstein, A. L., Costa, F., Giuliani, N., Pistoia, V., & Malavasi, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02722 · Cited by 176
How molecular imaging is speeding up antiangiogenic drug development
Cai, W., Rao, J., Gambhir, S. S., & Chen, X. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0395 · Cited by 175
Self-citationJungbluth, A. A., Stockert, E., Huang, H. J. S., Collins, V. P., Coplan, K., Iversen, K., Kolb, D., Johns, T. J., Scott, A. M., Gullick, W. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232686499 · Cited by 174
131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
D'Huyvetter, M., De Vos, J., Xavier, C., Pruszynski, M., Sterckx, Y. G. J., Massa, S., Raes, G., Caveliers, V., Zalutsky, M. R., Lahoutte, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0310 · Cited by 173
B7-H3 in Cancer – Beyond Immune Regulation
Flem-Karlsen, K., Fodstad, Ø., Tan, M., & Nunes-Xavier, C. E. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.03.010 · Cited by 172
Practical Theoretic Guidance for the Design of Tumor-Targeting Agents
Wittrup, K. D., Thurber, G. M., Schmidt, M. M., & Rhoden, J. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-396962-0.00010-0 · Cited by 171
A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer
Rosen, L. S., Hurwitz, H. I., Wong, M. K., Goldman, J., Mendelson, D. S., Figg, W. D., Spencer, S., Adams, B. J., Alvarez, D., Seon, B. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0098 · Cited by 170
PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody
Lv, G., Sun, X., Qiu, L., Sun, Y., Li, K., Liu, Q., Zhao, Q., Qin, S., & Lin, J. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.226712 · Cited by 168
Natarajan, A., Mayer, A. T., Xu, L., Reeves, R. E., Gano, J., & Gambhir, S. S. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00318 · Cited by 167
Santangelo, P. J., Rogers, K. A., Zurla, C., Blanchard, E. L., Gumber, S., Strait, K., Connor-Stroud, F., Schuster, D. M., Amancha, P. K., Hong, J. J., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3320 · Cited by 167
Schwager, K., Kaspar, M., Bootz, F., Marcolongo, R., Paresce, E., Neri, D., & Trachsel, E. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2814 · Cited by 167
Engineered antibody fragments for immuno-PET imaging of endogenous CD8 + T cells in vivo
Tavaré, R., McCracken, M. N., Zettlitz, K. A., Knowles, S. M., Salazar, F. B., Olafsen, T., Witte, O. N., & Wu, A. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316922111 · Cited by 166
Deri, M. A., Ponnala, S., Zeglis, B. M., Pohl, G., Dannenberg, J. J., Lewis, J. S., & Francesconi, L. C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500389b · Cited by 166
Engineered antibodies for molecular imaging of cancer
Wu, A. M. (2014) · Methods · doi:10.1016/j.ymeth.2013.09.015 · Cited by 166
PET Tracers Based on Zirconium-89
Zhang, Y., Hong, H., & Cai, W. (2011) · Current Radiopharmaceuticalse · doi:10.2174/1874471011104020131 · Cited by 166
Self-citationNguyen, Q.-D., Smith, G., Glaser, M., Perumal, M., Årstad, E., & Aboagye, E. O. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901310106 · Cited by 166
van Driel, P. B. A. A., Boonstra, M. C., Slooter, M. D., Heukers, R., Stammes, M. A., Snoeks, T. J. A., de Bruijn, H. S., van Diest, P. J., Vahrmeijer, A. L., van Bergen en Henegouwen, P. M. P., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.03.014 · Cited by 166
Modak, S. I., Kramer, K., Gultekin, S. H., Guo, H.-F., & Cheung, N. V. (2001) · PubMed · Cited by 164
Josefsson, A., Nedrow, J. R., Park, S., Banerjee, S. R., Rittenbach, A., Jammes, F., Tsui, B., & Sgouros, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2141 · Cited by 164
Zeglis, B. M., Mohindra, P., Weissmann, G. I., Divilov, V., Hilderbrand, S. A., Weissleder, R., & Lewis, J. S. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200288d · Cited by 162
Klinger, M., Benjamin, J., Kischel, R., Stienen, S., & Zugmaier, G. (2016) · Immunological Reviews · doi:10.1111/imr.12393 · Cited by 162
Anti–CTLA-4 therapy requires an Fc domain for efficacy
Ingram, J. R., Blomberg, O. S., Rashidian, M., Ali, L. R., Garforth, S., Fedorov, E. V., Fedorov, A. A., Bonanno, J. B., Gall, C. M. L., Crowley, S. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801524115 · Cited by 162
Recent Advances in Lgr5 + Stem Cell Research
Leung, C., Tan, S. H., & Barker, N. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.01.010 · Cited by 161
Zeglis, B. M., Davis, C. B., Aggeler, R., Kang, H. C., Chen, A., Agnew, B. J., & Lewis, J. S. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400122c · Cited by 160
Kramer-Marek, G., Kiesewetter, D. O., Martiniova, L., Jagoda, E., Lee, S. B., & Capala, J. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0658-0 · Cited by 160
Blykers, A., Schoonooghe, S., Xavier, C., D’hoe, K., Laoui, D., D’Huyvetter, M., Vaneycken, I., Cleeren, F., Bormans, G., Heemskerk, J., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.156828 · Cited by 160
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
Runcie, K., Budman, D. R., John, V., & Seetharamu, N. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0051-4 · Cited by 160
Xing, Y., Chand, G., Liu, C., Cook, G. J. R., O’Doherty, J., Zhao, L., Wong, N. C. L., Meszaros, L. K., Ting, H. H., & Zhao, J. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224170 · Cited by 160
Thiacycloalkynes for Copper‐Free Click Chemistry
de Almeida, G., Sletten, E. M., Nakamura, H., Palaniappan, K. K., & Bertozzi, C. R. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201106325 · Cited by 158
Kimura, R. H., Cheng, Z., Gambhir, S. S., & Cochran, J. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2495 · Cited by 158
Menke-van der Houven van Oordt, C. W., Gomez-Roca, C., van Herpen, C., Coveler, A. L., Mahalingam, D., Verheul, H. M. W., van der Graaf, W. T. A., Christen, R., Rüttinger, D., Weigand, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11098 · Cited by 158
PD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET
Lesniak, W. G., Chatterjee, S., Gabrielson, M., Lisok, A., Wharram, B. L., Pomper, M. G., & Nimmagadda, S. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00348 · Cited by 158
Fragomeni, R. A. S., Amir, T., Sheikhbahaei, S., Harvey, S. C., Javadi, M. S., Sólnes, L. B., Kiess, A. P., Allaf, M. E., Pomper, M. G., Gorin, M. A., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203570 · Cited by 158
Jailkhani, N., Ingram, J. R., Rashidian, M., Rickelt, S., Tian, C., Mak, H. H., Jiang, Z.-G., Ploegh, H. L., & Hynes, R. O. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817442116 · Cited by 158
89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
Pandit-Taskar, N. D., O’Donoghue, J. A., Beylergil, V., Lyashchenko, S. K., Ruan, S., Solomon, S. B., Durack, J. C., Carrasquillo, J. A., Lefkowitz, R. A., Gönen, M., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2830-7 · Cited by 156
Imaging activated T cells predicts response to cancer vaccines
Alam, I. S., Mayer, A. T., Sagiv-Barfi, I., Wang, K., Vermesh, O., Czerwinski, D. K., Johnson, E. M., James, M. L., Levy, R., & Gambhir, S. S. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98509 · Cited by 156
Forero, A., Weiden, P. L., Vose, J. M., Knox, S. J., LoBuglio, A. F., Hankins, J. H., Goris, M. L., Picozzi, V. J., Axworthy, D. B., Breitz, H. B., et al. (2004) · Blood · doi:10.1182/blood-2003-09-3284 · Cited by 155
Mandikian, D., Takahashi, N., Lo, A. A., Li, J., Eastham-Anderson, J., Slaga, D., Ho, J., Hristopoulos, M., Clark, R., Totpal, K., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0657 · Cited by 155
Orlova, A., Wållberg, H., Stone-Elander, S., & Tolmachev, V. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057919 · Cited by 152
Cai, W., Zhang, X., Wu, Y., & Chen, X. S. (2006) · PubMed · Cited by 150
Self-citationSortase A: A Model for Transpeptidation and Its Biological Applications
Pishesha, N., Ingram, J. R., & Ploegh, H. L. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062527 · Cited by 150
Bensch, F., Brouwers, A. H., Hooge, M. N. L., de Jong, J. R., van der Vegt, B., Sleijfer, S., de Vries, E. G. E., & Schröder, C. P. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4099-8 · Cited by 149
Gainkam, L. O. T., Caveliers, V., Devoogdt, N., Vanhove, C., Xavier, C., Boerman, O. C., Muyldermans, S., Bossuyt, A. M., & Lahoutte, T. (2010) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.408 · Cited by 148
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody
Sharkey, R. M., Cardillo, T. M., Rossi, E. A., Chang, C., Karacay, H., McBride, W. J., Hansen, H. J., Horak, I. D., & Goldenberg, D. M. (2005) · Nature Medicine · doi:10.1038/nm1322 · Cited by 148
Endoscopic molecular imaging of human bladder cancer using a CD47 antibody
Pan, Y., Volkmer, J.-P., Mach, K. E., Rouse, R. V., Liu, J., Sahoo, D., Chang, T., Metzner, T. J., Kang, L., van de Rijn, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009457 · Cited by 146
Self-citationPandit-Taskar, N. D., O’Donoghue, J. A., Ruan, S., Lyashchenko, S. K., Carrasquillo, J. A., Heller, G., Martinez, D. F., Cheal, S. M., Lewis, J. S., Fleisher, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.176206 · Cited by 146
Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer
Tagawa, S. T., Beltran, H., Vallabhajosula, S., Goldsmith, S. J., Osborne, J. R., Matulich, D., Petrillo, K., Parmar, S., Nanus, D. M., & Bander, N. H. (2010) · Cancer · doi:10.1002/cncr.24795 · Cited by 144
Chatalic, K. L. S., Veldhoven-Zweistra, J., Bolkestein, M., Hoeben, S. A. H., Koning, G. A., Boerman, O. C., de Jong, M., & van Weerden, W. M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.156729 · Cited by 144
Goldenberg, D. M., Rossi, E. A., Sharkey, R. M., McBride, W. J., & Chang, C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.046185 · Cited by 143
Encell, L. P. (2012) · Current Chemical Genomics · doi:10.2174/1875397301206010055 · Cited by 143
OX40: Structure and function – What questions remain?
Willoughby, J. E., Griffiths, J., Tews, I., & Cragg, M. S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.01.006 · Cited by 143
Immuno-imaging using nanobodies
Vaneycken, I., D’Huyvetter, M., Hernot, S., Vos, J. D., Xavier, C., Devoogdt, N., Caveliers, V., & Lahoutte, T. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.009 · Cited by 142
The Growing Impact of Bioorthogonal Click Chemistry on the Development of Radiopharmaceuticals
Zeng, D., Zeglis, B. M., Lewis, J. S., & Anderson, C. J. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.115550 · Cited by 142
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
Kratochwil, C., Schmidt, K. F., Afshar‐Oromieh, A., Bruchertseifer, F., Rathke, H. G., Morgenstern, A., Haberkorn, U., & Giesel, F. L. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3817-y · Cited by 142
Wong, A. N. M., McArthur, G. A., Hofman, M. S., & Hicks, R. J. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3691-7 · Cited by 141
Pereira, P. M. R., Sharma, S. K., Carter, L. M., Edwards, K. J., Pourat, J., Ragupathi, A., Janjigian, Y. Y., Durack, J. C., & Lewis, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-07608-w · Cited by 140
Localized CD47 blockade enhances immunotherapy for murine melanoma
Ingram, J. R., Blomberg, O. S., Sockolosky, J. T., Ali, L. R., Schmidt, F. I., Pishesha, N., Espinosa, C. A., Dougan, S. K., García, K. C., Ploegh, H. L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710776114 · Cited by 139
Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.
Deb, N., Goris, M. L., Trisler, K. D., Fowler, S., Saal, J. D., Ning, S., Becker, M., Marquez, C., & Knox, S. J. (1996) · PubMed · Cited by 138
Vos, J. D., Devoogdt, N., Lahoutte, T., & Muyldermans, S. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.800478 · Cited by 138
89Zr-cetuximab PET imaging in patients with advanced colorectal cancer
van Oordt, C. W. M. D. H., Gootjes, E. C., Huisman, M. C., Vugts, D. J., Roth, C., Luik, A. M., Mulder, E. R., Schuit, R. C., Boellaard, R., Hoekstra, O. S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4672 · Cited by 137
Ulaner, G. A., Hyman, D. M., Lyashchenko, S. K., Lewis, J. S., & Carrasquillo, J. A. (2017) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001820 · Cited by 137
Slaga, D., Ellerman, D. A., Lombana, T. N., Vij, R., Li, J., Hristopoulos, M. L., Clark, R., Johnston, J., Shelton, A., Mai, E., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat5775 · Cited by 137
A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer
Crawford, A., Haber, L., Kelly, M. P., Vazzana, K., Canova, L., Ram, P., Pawashe, A., Finney, J., Jalal, S., Chiu, D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7534 · Cited by 135
ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo
Rolle, A.-M., Hasenberg, M., Thornton, C. R., Solouk-Saran, D., Männ, L., Weski, J., Maurer, A., Fischer, E., Spycher, P. R., Schibli, R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518836113 · Cited by 134
Endoglin-Targeted Cancer Therapy
Seon, B. K., Haba, A., Matsuno, F., Takahashi, N., Tsujie, M., She, X., Harada, N., Uneda, S., Tsujie, T., Toi, H., et al. (2010) · Current Drug Delivery · doi:10.2174/156720111793663570 · Cited by 134
Johns, T. G., Stockert, E., Ritter, G., Jungbluth, A. A., Huang, H.-J. S., Cavenee, W. K., Smyth, F. E., Hall, C. M., Watson, N., Nice, E. C., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10189 · Cited by 134
Liersch, T., Meller, J., Kulle, B., Behr, T. M., Markus, P. M., Langer, C., Ghadimi, Β. M., Wegener, W. A., Kovacs, J., Horak, I. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.18.622 · Cited by 134
New insights into the pretargeting approach to image and treat tumours
Patra, M., Zarschler, K., Pietzsch, H., Stephan, H., & Gasser, G. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00784d · Cited by 134
PD-L1 is an activation-independent marker of brown adipocytes
Ingram, J. R., Dougan, M. L., Rashidian, M., Knoll, M., Keliher, E. J., Garrett, S., Garforth, S., Blomberg, O. S., Espinosa, C. A., Bhan, A. K., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00799-8 · Cited by 133
Imaging PD-L1 Expression with ImmunoPET
Truillet, C., Oh, H. L. J., Yeo, S. P., Lee, C., Huynh, L. T., Wei, J., Parker, M. F. L., Blakely, C. M., Sevillano, N., Wang, Y.-H., et al. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00631 · Cited by 133
Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology
Krasniqi, A., D’Huyvetter, M., Devoogdt, N., Frejd, F. Y., Sørensen, J. C. H., Orlova, A., Keyaerts, M., & Максимилианович, Т. В. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.199901 · Cited by 133
Larimer, B. M., Bloch, E., Nesti, S., Austin, E. E., Wehrenberg-Klee, E. P., Boland, G. M., & Mahmood, U. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2407 · Cited by 133
Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy
Larimer, B. M., Wehrenberg-Klee, E. P., Caraballo, A., & Mahmood, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.173930 · Cited by 131
Technology Insight: monoclonal antibody imaging of prostate cancer
Bander, N. H. (2006) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0452 · Cited by 130
Zaťovičová, M., Jelenska, L., Hulíková, A., Csáderová, L., Ditte, Z., Ditte, P., Golias, T., Pastorek, J., & Pastoreková, S. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793429832 · Cited by 129
Molecular advances in pretargeting radioimunotherapy with bispecific antibodies.
Chang, C., Sharkey, R. M., Rossi, E. A., Karacay, H., McBride, W., Hansen, H. J., Chatal, J., Barbet, J., & Goldenberg, D. M. (2002) · PubMed · Cited by 129
Chen, L., Cohen, J. D., Song, X., Zhao, A., Ye, Z., Feulner, C. J., Doonan, P. J., Somers, W., Lin, L., & Chen, P. R. (2016) · Scientific Reports · doi:10.1038/srep31899 · Cited by 129
Vosjan, M. J. W. D., Perk, L. R., Roovers, R. C., Visser, G. W. M., van Walsum, M., Henegouwen, P. M. P. V. B. E., & van Dongen, G. A. M. S. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1700-1 · Cited by 128
O’Donoghue, J. A., Lewis, J. S., Pandit-Taskar, N. D., Fleming, S. E., Schöder, H. M., Larson, S. M., Beylergil, V., Ruan, S., Lyashchenko, S. K., ZANZONICO, P. B., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.194555 · Cited by 127
89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer
England, C. G., Jiang, D., Ehlerding, E. B., Rekoske, B. T., Ellison, P. A., Hernandez, R. T., Barnhart, T. E., McNeel, D. G., Huang, P., & Cai, W. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3803-4 · Cited by 126
Self-citationFc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models
Sharma, S. K., Chow, A. T., Monette, S., Vivier, D., Pourat, J., Edwards, K. J., Dilling, T. R., Abdel-Atti, D., Zeglis, B. M., Poirier, J. T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1958 · Cited by 126
Massa, S., Vikani, N. A., Betti, C., Ballet, S., Vanderhaegen, S., Steyaert, J., Descamps, B., Vanhove, C., Bunschoten, A., van Leeuwen, F. W. B., et al. (2016) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1696 · Cited by 125
Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer
Sharma, S. K., Pourat, J., Abdel-Atti, D., Carlin, S. D., Piersigilli, A., Bankovich, A. J., Gardner, E. E., Hamdy, O., Isse, K., Bheddah, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0299 · Cited by 125
Targeting prostate cancer: Prostate‐specific membrane antigen based diagnosis and therapy
Wüstemann, T., Haberkorn, U., Babich, J. W., & Mier, W. (2018) · Medicinal Research Reviews · doi:10.1002/med.21508 · Cited by 125
Nagengast, W. B., Hooge, M. N. L., Oosting, S. F., den Dunnen, W. F. A., Warnders, F.-J., Brouwers, A. H., de Jong, J. R., Price, P., Hollema, H., Hospers, G. A. P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1088 · Cited by 124
Bartolo, N. M. D., Sargeson, A. M., & Smith, S. V. (2006) · Organic & Biomolecular Chemistry · doi:10.1039/b605615f · Cited by 124
Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery
Debie, P., Devoogdt, N., & Hernot, S. (2019) · Antibodies · doi:10.3390/antib8010012 · Cited by 124
Butelase-mediated cyclization and ligation of peptides and proteins
Nguyen, G. K. T., Qiu, Y., Cao, Y., Hemu, X., Liu, C., & Tam, J. P. (2016) · Nature Protocols · doi:10.1038/nprot.2016.118 · Cited by 122
Noninvasive PET Imaging of T cells
Wei, W., Jiang, D., Ehlerding, E. B., Luo, Q., & Cai, W. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.03.009 · Cited by 122
Self-citationGaykema, S. B. M., Schröder, C. P., Vitfell-Rasmussen, J., Chua, S. C., Munnink, T. H. O., Brouwers, A. H., Bongaerts, A. H. H., Akimov, M., Fernandez‐Ibarra, C., Hooge, M. N. L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0491 · Cited by 121
Cyclotron production of 44Sc: From bench to bedside
van der Meulen, N. P., Bunka, M., Domnanich, K. A., Müller, C., Haller, S., Vermeulen, C. E., Türler, A., & Schibli, R. (2015) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2015.05.005 · Cited by 120
Dynamic visualization of a joint-specific autoimmune response through positron emission tomography
Wipke, B. T., Wang, Z., Kim, J., McCarthy, T. J., & Allen, P. M. (2002) · Nature Immunology · doi:10.1038/ni775 · Cited by 120
Cai, W., Olafsen, T., Zhang, X., Cao, Q., Gambhir, S. S., Williams, L. E., Wu, A. M., & Chen, X. S. (2007) · PubMed · Cited by 120
Self-citationImmuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody
Li, D., Cheng, S., Zou, S., Zhu, D., Zhu, T., Wang, P., & Zhu, X. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00062 · Cited by 120
Yang, K., Basu, A., Wang, M., Chintala, R., Hsieh, M.-C., Liu, S., Hua, J., Zhang, Z., Zhou, J. M., Li, M., et al. (2003) · Protein Engineering Design and Selection · doi:10.1093/protein/gzg093 · Cited by 119
Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer
Pruszyński, M., D’Huyvetter, M., Bruchertseifer, F., Morgenstern, A., & Lahoutte, T. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00985 · Cited by 119
Ahlgren, S., Wållberg, H., Tran, T. A., Widström, C., Hjertman, M., Abrahmsén, L., Berndorff, D., Dinkelborg, L. M., Cyr, J. E., Feldwisch, J., et al. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.056929 · Cited by 118
Higashikawa, K., Yagi, K., Watanabe, K., Kamino, S., Ueda, M., Hiromura, M., & Enomoto, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109866 · Cited by 118
PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models
Niu, G., Li, Z., Xie, J., Le, Q., & Chen, X. S. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.061820 · Cited by 118
Tailoring antibodies for radionuclide delivery
Kenanova, V. E., & Wu, A. M. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.1.53 · Cited by 118
First-in-human uPAR PET: Imaging of Cancer Aggressiveness
Persson, M., Skovgaard, D. C., Brandt-Larsen, M., Christensen, C. L., Madsen, J., Nielsen, C. H., Thurison, T., Klausen, T. L., Holm, S., Loft, A., et al. (2015) · Theranostics · doi:10.7150/thno.12956 · Cited by 118
Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles
Kintzing, J. R., & Cochran, J. R. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.08.022 · Cited by 118
Yan, J., Li, G., Hu, Y., Ou, W., & Wan, Y. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0343-6 · Cited by 117
Ferdani, R., Stigers, D. J., Fiamengo, A. L., Wei, L., Li, B. T. Y., Golen, J. A., Rheingold, A. L., Weisman, G. R., Wong, E. H., & Anderson, C. J. (2011) · Dalton Transactions · doi:10.1039/c1dt11743b · Cited by 116
44Sc: An Attractive Isotope for Peptide-Based PET Imaging
Hernandez, R., Valdovinos, H. F., Yang, Y., Chakravarty, R., Hong, H., Barnhart, T. E., & Cai, W. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500343j · Cited by 116
Self-citationPractical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging
Mayer, A. T., Natarajan, A., Gordon, S. R., Maute, R. L., McCracken, M. N., Ring, A. M., Weissman, I. L., & Gambhir, S. S. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.177659 · Cited by 116
Creaney, J., Francis, R. J., Dick, I. M., Musk, A. W., Robinson, B. W. S., Byrne, M., & Nowak, A. K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1929 · Cited by 115
Oosting, S. F., Brouwers, A. H., van Es, S. C., Nagengast, W. B., Munnink, T. H. O., Hooge, M. N. L., Hollema, H., de Jong, J. R., de Jong, I. J., de Haas, S., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.144840 · Cited by 115
Kikuchi, M., Clump, D. A., Srivastava, R. M., Sun, L., Zeng, D., Díaz-Pérez, J. A., Anderson, C. J., Edwards, W. B., & Ferris, R. L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1329071 · Cited by 115
Olafsen, T., Cheung, C. W., Yazaki, P. J., Li, L., Sundaresan, G., Gambhir, S. S., Sherman, M. A., Williams, L. E., Shively, J. E., Raubitschek, A. A., et al. (2004) · Protein Engineering Design and Selection · doi:10.1093/protein/gzh009 · Cited by 114
Mirschberger, C., Schiller, C., Schräml, M., Dimoudis, N., Friess, T., Gerdes, C. A., Reiff, U., Lifke, V., Hoelzlwimmer, G., Kolm, I., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0099 · Cited by 114
Nagengast, W. B., de Korte, M. A., Munnink, T. H. O., Timmer‐Bosscha, H., den Dunnen, W. F. A., Hollema, H., de Jong, J. R., Jensen, M. R., Quadt, C., García-Echeverría, C., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.071043 · Cited by 113
Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?
Cutsem, E. V., Lambrechts, D., Prenen, H., Jain, R. K., & Carmeliet, P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2701 · Cited by 113
Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis
Senders, M. L., Hernot, S., Carlucci, G., van de Voort, J. C., Fay, F., Calcagno, C., Tang, J., Alaarg, A., Zhao, Y., Ishino, S., et al. (2018) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2018.07.027 · Cited by 113
Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
Yuraszeck, T. M., Kasichayanula, S., & Benjamin, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.651 · Cited by 112
18 F‐Labeling of Sensitive Biomolecules for Positron Emission Tomography
Krishnan, H. S., Ma, L., Vasdev, N., & Liang, S. H. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201701581 · Cited by 112
Nanobody–photosensitizer conjugates for targeted photodynamic therapy
Heukers, R., Henegouwen, P. M. P. V. B. E., & Oliveira, S. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.12.007 · Cited by 111
Guérard, F., Lee, Y. S., Tripier, R., Szajek, L. P., Deschamps, J. R., & Brechbiel, M. W. (2012) · Chemical Communications · doi:10.1039/c2cc37549d · Cited by 111
Максимилианович, Т. В., Nilsson, F. Y., Widström, C., Andersson, K., Rosik, D., Gedda, L., Wennborg, A., & Orlova, A. (2006) · PubMed · Cited by 111
Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
McBride, W. J., ZANZONICO, P. B., Sharkey, R. M., Norén, C., Karacay, H., Rossi, E. A., Losman, M. J., Brard, P.-Y., Chang, C., Larson, S. M., et al. (2006) · PubMed · Cited by 111
Radioiodine: The Classic Theranostic Agent
Silberstein, E. B. (2012) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2011.12.002 · Cited by 110
Ahlskog, J., Schliemann, C., Mårlind, J., Qureshi, U., Ammar, A., Pedley, R. B., & Neri, D. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605200 · Cited by 110
Sandström, M., Lindskog, K., Velikyan, I., Wennborg, A., Feldwisch, J., Sandberg, D., Максимилианович, Т. В., Orlova, A., Sørensen, J., Carlsson, J., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.169342 · Cited by 110
Laverman, P., van der Geest, T., Terry, S. Y. A., Gerrits, D., Walgreen, B., Helsen, M. M. A., Nayak, T. K., Freimoser–Grundschober, A., Waldhauer, I., Hosse, R. J., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.152959 · Cited by 109
Pretargeted Molecular Imaging and Radioimmunotherapy
Goldenberg, D. M., Chang, C., Rossi, E. A., McBride, W. J., & Sharkey, R. M. (2012) · Theranostics · doi:10.7150/thno.3582 · Cited by 109
Theranostics Using Antibodies and Antibody-Related Therapeutics
Moek, K. L., Giesen, D., Kok, I. C., de Groot, D. J. A., Jalving, M., Fehrmann, R. S. N., Hooge, M. N. L., Brouwers, A. H., & de Vries, E. G. E. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186940 · Cited by 109
Houghton, J. L., Membreno, R., Abdel-Atti, D., Cunanan, K. M., Carlin, S., Scholz, W. W., ZANZONICO, P. B., Lewis, J. S., & Zeglis, B. M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0503 · Cited by 108
Sachpekidis, C., Anwar, H., Winkler, J. K., Kopp‐Schneider, A., Larribère, L., Haberkorn, U., Hassel, J. C., & Dimitrakopoulou‐Strauss, A. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3972-9 · Cited by 108
Natarajan, A., Mayer, A. T., Reeves, R. E., Nagamine, C. M., & Gambhir, S. S. (2017) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1060-3 · Cited by 107
Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies
Langbein, T., Chaussé, G., & Baum, R. P. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.214379 · Cited by 107
Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
Lamberts, L. E., Williams, S. P., van Scheltinga, A. G. T. T., Hooge, M. N. L., Schröder, C. P., Gietema, J. A., Brouwers, A. H., & de Vries, E. G. E. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.8278 · Cited by 106
Muylle, K., Flamen, P., Vugts, D. J., Guiot, T., Ghanem, G., Meuleman, N., Bourgeois, P., Vanderlinden, B., van Dongen, G. A. M. S., Everaert, H., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3025-6 · Cited by 105
Human Monoclonal Antibodies to Sialyl-Lewisa (CA19.9) with Potent CDC, ADCC, and Antitumor Activity
Sawada, R., Sun, S.-M., Wu, X., Hong, F., Ragupathi, G., Livingston, P. O., & Scholz, W. W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2640 · Cited by 105
Houghton, J. L., Zeglis, B. M., Abdel-Atti, D., Aggeler, R. J., Sawada, R., Agnew, B. J., Scholz, W. W., & Lewis, J. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1506542112 · Cited by 105
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
den Hollander, M. W., Bensch, F., Glaudemans, A. W. J. M., Munnink, T. H. O., Enting, R. H., den Dunnen, W. F. A., Heesters, M. A. A. M., Kruyt, F. A. E., Hooge, M. N. L., de Groot, J. C., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154401 · Cited by 104
Pishvaian, M. J., Morse, M. A., McDevitt, J. T., Norton, J., Ren, S., Robbie, G. J., Ryan, P. C., Soukharev, S., Bao, H., & Denlinger, C. S. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.07.009 · Cited by 104
124I-huA33 Antibody PET of Colorectal Cancer
Carrasquillo, J. A., Pandit-Taskar, N. D., O’Donoghue, J. A., Humm, J. L., ZANZONICO, P. B., Smith-Jones, P. M., Divgi, C. R., Pryma, D. A., Ruan, S., Kemeny, N. E., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.086165 · Cited by 103
A modular IgG-scFv bispecific antibody topology
Orcutt, K. D., Ackerman, M. E., Cieslewicz, M., Quiroz, E., Slusarczyk, A. L., Frangioni, J. V., & Wittrup, K. D. (2009) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp077 · Cited by 102
In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET
Trotter, D. E. G., Meng, X., Mcquade, P. S., Rubins, D. J., Klimas, M. T., Zeng, Z., Connolly, B., Miller, P. J., O'Malley, S. S., Lin, S.-A., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191718 · Cited by 102
Beckford-Vera, D., Smith, C. C., Bixby, L. M., Glatt, D. M., Dunn, S. S., Saito, R., Kim, W. Y., Serody, J. S., Vincent, B. G., & Parrott, M. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193832 · Cited by 102
Schoffelen, R., Sharkey, R. M., Goldenberg, D. M., Franssen, G. M., McBride, W. J., Rossi, E. A., Chang, C., Laverman, P., Disselhorst, J. A., Eek, A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0862 · Cited by 101
Tijink, B. M., Perk, L. R., Budde, M., van Walsum, M., Visser, G. W. M., Kloet, R. W., Dinkelborg, L. M., Leemans, C. R., Neri, D., & van Dongen, G. A. M. S. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1096-y · Cited by 101
Schiefner, A., & Skerra, A. (2015) · Accounts of Chemical Research · doi:10.1021/ar5003973 · Cited by 100
Evaluation of Bifunctional Chelates for the Development of Gallium-Based Radiopharmaceuticals
Ferreira, C. L., Lamsa, E., Woods, M., Duan, Y., Fernando, P., Bensimon, C., Kordos, M., Guenther, K. J., Jurek, P. E., & Kiefer, G. E. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900443a · Cited by 100
Corso, S., & Giordano, S. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0040 · Cited by 100
Lamberts, L. E., van Oordt, C. W. M. D. H., ter Weele, E. J., Bensch, F., Smeenk, M. M., Voortman, J., Hoekstra, O. S., Williams, S. P., Fine, B. M., Maslyar, D. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1272 · Cited by 100
ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer
Ehlerding, E. B., England, C. G., Majewski, R. L., Valdovinos, H. F., Jiang, D., Liu, G., McNeel, D. G., Nickles, R. J., & Cai, W. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00056 · Cited by 100
Self-citationIFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy
Gibson, H. M., McKnight, B. N., Malysa, A., Dyson, G. E., Wiesend, W. N., McCarthy, C. E., Reyes, J. D., Wei, W., & Viola, N. T. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0253 · Cited by 100
Self-citationBerg, E., Gill, H. S., Mařı́k, J., Ogasawara, A. K., Williams, S. P., van Dongen, G. A. M. S., Vugts, D. J., Cherry, S. R., & Tarantal, A. F. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.230961 · Cited by 100
Schoffelen, R., Boerman, O. C., Goldenberg, D. M., Sharkey, R. M., van Herpen, C. M. L., Franssen, G. M., McBride, W. J., Chang, C.-H., Rossi, E. A., van der Graaf, W. T. A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.376 · Cited by 98
Noninvasive positron emission tomography and fluorescence imaging of CD133 + tumor stem cells
Gaedicke, S., Braun, F., Prasad, S., Machein, M. R., Firat, E., Hettich, M., Gudihal, R., Zhu, X., Klingner, K., Schüler, J. B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314189111 · Cited by 98
Ahlgren, S., Orlova, A., Wållberg, H., Hansson, M., Sandström, M., Lewsley, R., Wennborg, A., Abrahmsén, L., Максимилианович, Т. В., & Feldwisch, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.073346 · Cited by 97
Krämer-Marek, G., Kiesewetter, D. O., & Capala, J. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057695 · Cited by 97
Vaidyanathan, G., McDougald, D. L., Choi, J., Koumarianou, E., Weitzel, D. H., Osada, T., Lyerly, H. K., & Zalutsky, M. R. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171306 · Cited by 97
Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
Donin, N. M., & Reiter, R. E. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191874 · Cited by 97
Paterson, B. M., Alt, K., Jeffery, C. M., Price, R. I., Jagdale, S., Rigby, S., Williams, C. C., Peter, K., Hagemeyer, C. E., & Donnelly, P. S. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201402613 · Cited by 96
Engineered antibodies: new possibilities for brain PET?
Sehlin, D., & Syvänen, S. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04426-0 · Cited by 96
Östman, A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.022 · Cited by 95
Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages
Xavier, C., Blykers, A., Laoui, D., Bolli, E., Vaneycken, I., Bridoux, J., Baudhuin, H. V., Raes, G., Everaert, H., Movahedi, K., et al. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-018-01302-5 · Cited by 95
One-step 18F labeling of biomolecules using organotrifluoroborates
Liu, Z., Lin, K., Bénard, F., Pourghiasian, M., Kiesewetter, D. O., Perrin, D. M., & Chen, X. S. (2015) · Nature Protocols · doi:10.1038/nprot.2015.090 · Cited by 94
A universal pretargeting system for cancer detection and therapy using bispecific antibody.
Sharkey, R. M., McBride, W. J., Karacay, H., Chang, K., Griffiths, G. L., Hansen, H. J., & Goldenberg, D. M. (2003) · PubMed · Cited by 94
Kolbert, K. S., Pentlow, K. S., Pearson, J. R., Sheikh, A., Finn, R. D., Humm, J. L., & Larson, S. M. (2007) · PubMed · Cited by 94
Heskamp, S., van Laarhoven, H. W. M., Molkenboer‐Kuenen, J. D. M., Franssen, G. M., Versleijen‐Jonkers, Y. M. H., Oyen, W. J. G., van der Graaf, W. T. A., & Boerman, O. C. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.075648 · Cited by 93
Molecular Imaging of Chemokine Receptor CXCR4
Weiss, I. D., & Jacobson, O. (2013) · Theranostics · doi:10.7150/thno.4835 · Cited by 93
Imaging of anticancer drug action in single cells
Miller, M. A., & Weissleder, R. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.41 · Cited by 92
Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX
Lau, J., Lin, K., & Bénard, F. (2017) · Theranostics · doi:10.7150/thno.21848 · Cited by 92
CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols
Seo, J. W., Tavaré, R., Mahakian, L. M., Silvestrini, M. T., Tam, S. M., Ingham, E. S., Salazar, F. B., Borowsky, A. D., Wu, A. M., & Ferrara, K. W. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0261 · Cited by 91
Molecular Drug Imaging: 89Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma
Jansen, M. H. A., van Zanten, S. E. M. V., van Vuurden, D. G., Huisman, M. C., Vugts, D. J., Hoekstra, O. S., van Dongen, G. A. M. S., & Kaspers, G. J. L. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.180216 · Cited by 90
Lindborg, M., Cortez, E., Höidén‐Guthenberg, I., Gunneriusson, E., von Hage, E., Syud, F. A., Morrison, M., Abrahmsén, L., Herne, N., Pietras, K., et al. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.01.033 · Cited by 89
Bockhorn, M., Tsuzuki, Y., Xu, L., Frilling, A., Broelsch, C. E., & Fukumura, D. (2003) · PubMed · Cited by 89
Replacing Antibodies: Engineering New Binding Proteins
Banta, S., Dooley, K., & Shur, O. (2013) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071812-152412 · Cited by 89
Elsässer‐Beile, U., Reischl, G., Wiehr, S., Bühler, P., Wolf, P., Alt, K., Shively, J. E., Judenhofer, M. S., Machulla, H. ‐., & Pichler, B. J. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058487 · Cited by 89
Pruszyński, M., Koumarianou, E., Vaidyanathan, G., Revets, H., Devoogdt, N., Lahoutte, T., Lyerly, H. K., & Zalutsky, M. R. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.127100 · Cited by 89
Al18F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging
Cleeren, F., Lecina, J., Ahamed, M., Raes, G., Devoogdt, N., Caveliers, V., Mcquade, P. S., Rubins, D. J., Li, W., Verbruggen, A., et al. (2017) · Theranostics · doi:10.7150/thno.20094 · Cited by 89
Cole, E. L., Kim, J., Donnelly, D. J., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.07.066 · Cited by 89
Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64
Wadas, T. J., & Anderson, C. J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.431 · Cited by 88
Bao, R., Wang, Y., Lai, J., Zhu, H., Zhao, Y., Li, S., Li, N., Huang, J., Yang, Z., Wang, F., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00997 · Cited by 88
Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy.
Knight, J. C., & Cornelissen, B. T. (2014) · Oxford University Research Archive (ORA) (University of Oxford) · Cited by 86
Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy
King, D., Antoniw, P., Owens, R. J., ADAIR, J., Haines, A., Farnsworth, A., Finney, H. M., Lawson, A., Lyons, A. T., Baker, T., et al. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.516 · Cited by 86
Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice
Cai, W., Ebrahimnejad, A., Chen, K., Cao, Q., Li, Z., Tice, D. A., & Chen, X. S. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0503-5 · Cited by 86
Self-citationThe chemistry of PET imaging with zirconium-89
Dilworth, J. R., & Pascu, S. I. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00014f · Cited by 86
Mayer, A. T., & Gambhir, S. S. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.185967 · Cited by 86
Salaün, P., Campion, L., Bournaud, C., Faivre-Chauvet, A., Vuillez, J.-P., Taïeb, D., Ansquer, C., Rousseau, C., Borson‐Chazot, F., Bardet, S., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.101865 · Cited by 85
Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL)
Weiden, P. L., & Breitz, H. B. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00133-0 · Cited by 85
Zeglis, B. M., Davis, C. B., Abdel-Atti, D., Carlin, S., Chen, A., Aggeler, R. J., Agnew, B. J., & Lewis, J. S. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500499h · Cited by 85
Wu, Y.-L. L. C., Soo, R. A., Locatelli, G., Stammberger, U. M., Scagliotti, G. V., & Park, K. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.003 · Cited by 84
Matsuda, M., Ishikawa, E., Yamamoto, T., Hatano, K., Joraku, A., Iizumi, Y., Masuda, Y., Nishiyama, H., & Matsumura, A. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2825-5 · Cited by 84
Cited by
Antibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
Guo, X., Li, Y., Zhang, M., Cao, K., Tian, Y., Qi, Y., Li, S., Li, K., Yu, X., & Ma, L. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202010829 · Cited by 345
Radiochemistry for positron emission tomography
Rong, J., Haider, A., Jeppesen, T. E., Josephson, L., & Liang, S. H. (2023) · Nature Communications · doi:10.1038/s41467-023-36377-4 · Cited by 294
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.002 · Cited by 280
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
“A variety of radionuclides and monoclonal antibodies have been used to develop immunoPET probes, which has been driven by advances in radiochemistry and conjugation strategies 152 .”
Background
Metadata
- Authors
- Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-03-23
- Volume
- 120
- Issue
- 8
- Pages
- 3787-3851
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W3012903956
- Cited by
- 484
- References
- 717
- FWCI
- 12.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.